Advanced search
Publication Cover
Leukemia & Lymphoma Volume 56, 2015 - Issue 5
Submit an article Journal homepage
885
Views
13
CrossRef citations to date
0
Altmetric
Letter to the Editor

Complete remission of CD30-positive diffuse large B-cell lymphoma in a patient with post-transplant lymphoproliferative disorder and end-stage renal disease treated with single-agent brentuximab vedotin

Brian T. HillDepartment of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USACorrespondence[email protected]
,
Raymond R. TubbsDepartment of Molecular Pathology, Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland, OH, USA
&
Mitchell R. SmithDepartment of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA
Pages 1552-1553 | Received 16 Jan 2014, Accepted 30 Mar 2014, Published online: 09 Apr 2014

Citations (13)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Amelie Kinch, Rose-Marie Amini, Peter Hollander, Daniel Molin, Christer Sundström & Gunilla Enblad. (2020) CD30 expression and survival in posttransplant lymphoproliferative disorders. Acta Oncologica 59:6, pages 673-680.
Read now
Jan Styczynski. (2017) Managing post-transplant lymphoproliferative disorder. Expert Opinion on Orphan Drugs 5:1, pages 19-35.
Read now

Articles from other publishers (10)

Aimee Schad, Abhinandan R Pakanati, Susan Woelich & Abhishek Chilkulwar. (2023) Safe prolonged use of brentuximab vedotin in a patient with Classical Hodgkin Lymphoma on hemodialysis. Current Problems in Cancer: Case Reports 11, pages 100249.
Crossref
Roland SchwartingEric BehlingAshleigh AllenVivian Arguello-GuerraTulin Budak-Alpdogan. (2022) CD30+ Lymphoproliferative Disorders as Potential Candidates for CD30-Targeted Therapies. Archives of Pathology & Laboratory Medicine 146:4, pages 415-432.
Crossref
Patrizia Comoli & Jan Styczynski. 2021. Post-Transplant Lymphoproliferative Disorders. Post-Transplant Lymphoproliferative Disorders 221 237 .
Rebecca E. Schultze-Florey & Britta Maecker-Kolhoff. (2018) Transplantationsassoziierte lymphoproliferative Erkrankungen (PTLD) bei KindernPost-transplant lymphoproliferative diseases in children. Zeitschrift für Herz-,Thorax- und Gefäßchirurgie 32:6, pages 502-509.
Crossref
Kaitlin Stanley, Erika Friehling, Sarangarajan Ranganathan, George Mazariegos, Linda M. McAllister-Lucas & Rakesh Sindhi. (2018) Post-transplant lymphoproliferative disorder in pediatric intestinal transplant recipients: A literature review. Pediatric Transplantation 22:5, pages e13211.
Crossref
Christopher Hartley, James W Vaughan, Jason Jarzembowski, Steven H Kroft, Paul Hosking, Alexandra M Harrington & Horatiu Olteanu. (2017) CD30 Expression in Monomorphic Posttransplant Lymphoproliferative Disorder, Diffuse Large B-Cell Lymphoma Correlates With Greater Regulatory T-Cell Infiltration. American Journal of Clinical Pathology 148:6, pages 485-493.
Crossref
Michael J. Absalon, Ruby A. Khoury & Christine L. Phillips. (2017) Post-transplant lymphoproliferative disorder after solid-organ transplant in children. Seminars in Pediatric Surgery 26:4, pages 257-266.
Crossref
. (2016) Brentuximab vedotin. Reactions Weekly 1583:1, pages 226-226.
Crossref
Toni K. Roberts, Xueyan Chen & Jay Justin Liao. (2016) Diagnostic and therapeutic challenges of EBV-positive mucocutaneous ulcer: a case report and systematic review of the literature. Experimental Hematology & Oncology 5:1.
Crossref
Sara Kleinman, Devi Jhaveri, Paolo Caimi, Robert Cameron, Tracy Lemonovich, Howard Meyerson, Robert Hostoffer & Haig Tcheurekdjian. (2014) A rare presentation of EBV+ mucocutaneous ulcer that led to a diagnosis of hypogammaglobulinemia. The Journal of Allergy and Clinical Immunology: In Practice 2:6, pages 810-812.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.